Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company that develops precision medicines for rare neuroendocrine diseases characterized by severe obesity and hyperphagia, particularly those caused by MC4R pathway genetic defects. The company's lead product, IMCIVREE (setmelanotide), is an MC4R agonist approved in multiple countries for treating obesity in patients with Bardet-Biedl syndrome and specific genetic deficiencies; the company is also developing next-generation MC4R agonists in oral and weekly injection formulations to expand its addressable patient population. Rhythm generates revenue through direct product sales via specialty pharmacies and distributors, licensing agreements with upstream partners that provide milestone and royalty payments, and a pipeline of label-expansion opportunities for its approved therapies and new indications including Prader-Willi syndrome and hypothalamic obesity.